Effect of natural killer T cell activation on initiation of atherosclerosis

Thrombosis and Haemostasis

Volumn 102, Issue 2, 2009, Pages 223-230

  Van Puijvelde, Gijs H M ^a   Van Wanrooij, Eva J A ^a   Hauer, Arnaud D ^a   De Vos, Paula ^a   Van Berkel, Theo J C ^a   Kuiper, Johan ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Cytokines; Immune response; NKT cells

Indexed keywords

APOLIPOPROTEIN E; CD1D ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; ALPHA GALACTOSYLCERAMIDE; ALPHA-GALACTOSYLCERAMIDE; CYTOKINE; GALACTOSYLCERAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ATHEROSCLEROSIS; CELL COUNT; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIETARY INTAKE; IN VITRO STUDY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; ANIMAL; ARTICLE; ATHEROGENIC DIET; BIOSYNTHESIS; CAROTID ARTERY DISEASE; DISEASE MODEL; DRUG EFFECT; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MALE; MOUSE MUTANT; PATHOLOGY;

ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CYTOKINES; DIET, ATHEROGENIC; DISEASE MODELS, ANIMAL; GALACTOSYLCERAMIDES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; RECEPTORS, LDL;

EID: 70350435777     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH09-01-0020     Document Type: Conference Paper

References (36)

1. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Annu Rev Immunol 2004; 22: 361-403.
2. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. Jul 2006; 6: 508-519.
3. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol 1989; 135: 169-175. (Pubitemid 19229001)
4. Stemme S, Faber B, Holm J, et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 1995; 92: 3893-3897.
5. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 2006; 26: 2421-2432.
6. Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002; 88: 554-567.
7. Davenport P, Tipping PG. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163: 1117-1125. (Pubitemid 37040147)
8. van Wanrooij EJ, van Puijvelde GH, de Vos P, et al. Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2007; 27: 204-210.
9. King VL, Szilvassy SJ, Daugherty A. Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice. Arterioscler Thromb Vasc Biol 2002; 22: 456-461. (Pubitemid 34218754)
10. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001; 413: 531-534. (Pubitemid 32938752)
11. Braunersreuther V, Mach F, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost 2007; 97: 714-721.
12. Franitza S, Grabovsky V, Wald O, et al. Differential usage of VLA-4 and CXCR4 by CD3+CD56+ NKT cells and CD56+CD16+ NK cells regulates their interaction with endothelial cells. Eur J Immunol 2004; 34: 1333-1341.
13. Bobryshev YV, Lord RS. Co-accumulation of dendritic cells and natural killer T cells within rupture-prone regions in human atherosclerotic plaques. J Histochem Cytochem 2005; 53: 781-785.
14. Bobryshev YV, Lord RS. Identification of natural killer cells in human atherosclerotic plaque. Atherosclerosis 2005; 180: 423-427. (Pubitemid 41072916)
15. Nakai Y, Iwabuchi K, Fujii S, et al. Natural killer T cells accelerate atherogenesis in mice. Blood 2004; 104: 2051-2059. (Pubitemid 39297856)
16. Tupin E, Nicoletti A, Elhage R, et al. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J Exp Med 2004; 199: 417-422. (Pubitemid 38252053)
17. Major AS, Wilson MT, McCaleb JL, et al. Quantitative and qualitative differences in proatherogenic NKT cells in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2004; 24: 2351-2357.
18. Ostos MA, Recalde D, Zakin MM, et al. Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. FEBS Lett 2002; 519: 23-29. (Pubitemid 34521986)
19. Aslanian AM, Chapman HA, Charo IF. Transient role for CD1d-restricted natural killer T cells in the formation of atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2005; 25: 628-632.
20. Vanderlaan PA, Reardon CA, Sagiv Y, et al. Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis. Am J Pathol 2007; 170: 1100-1107. (Pubitemid 47339376)
21. Hong S, Wilson MT, Serizawa I, et al. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat Med 2001; 7: 1052-1056. (Pubitemid 32937387)
22. Jahng AW, Maricic I, Pedersen B, et al. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med 2001; 194: 1789-1799. (Pubitemid 34028658)
23. Saubermann LJ, Beck P, De Jong YP, et al. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 2000; 119: 119-128. (Pubitemid 30452585)
24. Singh N, Hong S, Scherer DC, et al. Cutting edge: activation of NK T cells by CD1d and alpha-galactosyl-ceramide directs conventional T cells to the acquisition of a Th2 phenotype. J Immunol 1999; 163: 2373-2377. (Pubitemid 29399153)
25. Burdin N, Brossay L, Kronenberg M. Immunization with alpha- galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis. Eur J Immunol 1999; 29: 2014-2025. (Pubitemid 29265558)
26. van den Elzen P, Garg S, Leon L, et al. Apolipoprotein- mediated pathways of lipid antigen presentation. Nature 2005; 437: 906-910. (Pubitemid 41486768)
27. von der Thusen JH, van Berkel TJ, Biessen EA. Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation 2001; 103: 1164-1170.
28. Kawano T, Cui J, Koezuka Y, et al. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides. Science 1997; 278: 1626-1629. (Pubitemid 27516282)
29. Ortaldo JR, Young HA, Winkler-Pickett RT, et al. Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides. J Immunol 2004; 172: 943-953.
30. Karussis D, Michaelson DM, Grigoriadis N, et al. Lack of apolipoprotein-E exacerbates experimental allergic encephalomyelitis. Mult Scler 2003; 9: 476-480. (Pubitemid 37287727)
31. Jahng A, Maricic I, Aguilera C, et al. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004; 199: 947-957. (Pubitemid 38481086)
32. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47.
33. Pinderski LJ, Fischbein MP, Subbanagounder G, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002; 90: 1064-1071. (Pubitemid 34627904)
34. Von Der Thusen JH, Kuiper J, Fekkes ML, et al. Attenuation of atherogenesis by systemic and local adenovirus- mediated gene transfer of interleukin-10 in LDLr-/- mice. Faseb J 2001; 15: 2730-2732.
35. Boullier A, Bird DA, Chang MK, et al. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann NY Acad Sci 2001; 947: 214-223. (Pubitemid 34059916)
36. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8: 802-815.